Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

AkesoBio Completes $335 Million Hong Kong IPO; Climbs 50% on First Trading Day

publication date: Apr 24, 2020

AkesoBio, a Zhongshan developer of novel mono- and bi-specific antibodies, staged a $335 million Hong Kong IPO and climbed 50% higher in its first trading session. The company's general strategy is to develop bispecific antibodies using a PD-1 antibody as a backbone. It has built a portfolio of 18 mAbs that are in either CMC or clinical stages of development. Last year, Akeso formed a $100 million JV with a Sino Biopharma subsidiary to develop and commercialize AK105, its clinical-stage anti-PD-1 mAb. More details....

Stock Symbols: (HK: 9926) (HK:1177)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.